Tagged with EG

Opinion John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the past risk getting left behind.   “Drug” companies have a unique opportunity to invent a different market for themselves. It…

Belgium Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading the affiliate. Nolet goes on the elaborate on the vast commitment Roche has to the Belgian market and the company’s mission not only to drive innovation but…

Mexico Mauricio Guizar, newly appointed general manager of Ipsen Mexico since October 2019, shares his first impression of the French specialty care player’s operations in Mexico, the significance of being the first Mexican GM in the local market, as well as his focus on positioning Ipsen as a partner to the…

Morocco Saad Kanbris, who has been heading Novartis operations in Morocco, Tunisia & Libya since January 2018, discusses the importance of ‘the context’ and temporality while analyzing the improvement and the next steps for the Moroccan market and the region he manages.   It makes no sense to grow if there…

Romania Dan Minoiu, partner at Romanian law firm Mușat & Asociații, shares his insights into the main trends shaping the healthcare environment in Romania from a regulatory and legal perspective, the challenges currently facing his clients, and his hopes for the future of the country.   Our clients always stress how…

EFPIA The European Commission recently announced a new industrial strategy and pharmaceutical roadmap, largely focused on revising legislation dating back nearly two decades, with the aim of laying out a concrete plan by the end of 2020. The commission’s priority is to revitalize medical innovation in Europe, a chief concern voiced…

Morocco Alain Barry, managing director of MSD in Morocco, shares how the organization is partnering with the Moroccan healthcare community to ensure that patients have access to innovative therapies and vaccines.   Morocco has been a pioneer in the region in the field of immunization by introducing innovative vaccines in the…

Romania Sévan Kaloustian shares his first impressions of the Romanian healthcare ecosystem and pharmaceutical market as newly appointed managing director of Janssen Pharmaceutical Companies of Johnson & Johnson Romania. Kaloustian outlines his intention to maintain the strategic position of Janssen as a key player in Romania, working to facilitate the access…

Romania Arina Gholmieh introduces the Romanian affiliate of Egis, a leading pharma manufacturer in the Central and Eastern Europe (CEE) region. Gholmieh highlights the difficulties that pharma companies, and especially generic producers, face in Romania: clawback tax, pricing methodology, and a low penetration rate of biosimilar medicines.   We are passing…

Mexico Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key opinion leaders. Here, we round up three of their most talked about topics.   Government  One of the most talked-about…

Belgium Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an innovative specialty pharma player balancing a core business with an increasing focus on specialty areas. He also offers insights on…

Belgium Fréderic Covemaeker, general manager of Nordic Pharma Belgium, introduces the Belgian affiliate which he established himself in 2008 and elaborates on the next stage of development for operations as Nordic prepares to deliver new solutions to patients in areas with unmet medical needs. Covemaeker also speaks to the challenges faced…